Nightstar Therapeutics (NASDAQ: NITE) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Nightstar Therapeutics to related companies based on the strength of its earnings, risk, valuation, institutional ownership, dividends, profitability and analyst recommendations.
Insider & Institutional Ownership
27.1% of Nightstar Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Nightstar Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nightstar Therapeutics Competitors||867||3227||11711||232||2.71|
Nightstar Therapeutics presently has a consensus target price of $24.75, indicating a potential upside of 91.12%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.48%. Given Nightstar Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Nightstar Therapeutics is more favorable than its rivals.
Valuation and Earnings
This table compares Nightstar Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nightstar Therapeutics Competitors||$284.49 million||$34.10 million||81.71|
Nightstar Therapeutics’ rivals have higher revenue and earnings than Nightstar Therapeutics.
This table compares Nightstar Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nightstar Therapeutics Competitors||-5,279.13%||-223.55%||-40.34%|
Nightstar Therapeutics beats its rivals on 6 of the 10 factors compared.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.